Newamsterdam Pharma Stock Investor Sentiment
| NAMS Stock | 23.02 1.52 7.07% |
Slightly above 51% of NewAmsterdam Pharma's investor base is interested to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are impartial. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
Comfort Level 49
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use NewAmsterdam Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward NewAmsterdam Pharma.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
NewAmsterdam Historical Sentiment
Although NewAmsterdam Pharma's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding NewAmsterdam, such as negative comments on social media and news outlets, may cause fear in the market and push NewAmsterdam Pharma's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of NewAmsterdam.
NewAmsterdam |
NewAmsterdam Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NewAmsterdam Pharma Historical Investor Sentiment
Investor biases related to NewAmsterdam Pharma's public news can be used to forecast risks associated with an investment in NewAmsterdam. The trend in average sentiment can be used to explain how an investor holding NewAmsterdam can time the market purely based on public headlines and social activities around NewAmsterdam Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
NewAmsterdam Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for NewAmsterdam Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average NewAmsterdam Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on NewAmsterdam Pharma.
Far too much social signal, news, headlines, and media speculation about NewAmsterdam Pharma that are available to investors today. That information is available publicly through NewAmsterdam media outlets and privately through word of mouth or via NewAmsterdam internal channels. However, regardless of the origin, that massive amount of NewAmsterdam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NewAmsterdam Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NewAmsterdam Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NewAmsterdam Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NewAmsterdam Pharma alpha.
NewAmsterdam Pharma Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiov... | 12/10/2024 |
2 | Disposition of 4894 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 27.109 subject to Rule 16b-3 | 12/11/2024 |
3 | Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicet... | 12/16/2024 |
4 | Disposition of 56506 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.4452 subject to Rule 16b-3 | 12/19/2024 |
5 | Disposition of 5629 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 26.1274 subject to Rule 16b-3 | 12/20/2024 |
6 | Disposition of 25132 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.4904 subject to Rule 16b-3 | 12/23/2024 |
7 | Disposition of 16164 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.66 subject to Rule 16b-3 | 12/24/2024 |
8 | Disposition of 33438 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 26.0072 subject to Rule 16b-3 | 12/26/2024 |
9 | Disposition of 41472 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.9522 subject to Rule 16b-3 | 12/27/2024 |
10 | Acquisition by Kastelein Johannes Jacob Pieter of 200000 shares of NewAmsterdam Pharma at 25.96 subject to Rule 16b-3 | 01/02/2025 |
11 | Acquisition by Davidson Michael H. of 670467 shares of NewAmsterdam Pharma at 25.85 subject to Rule 16b-3 | 01/06/2025 |
12 | Acquisition by Mayur Somaiya of 38000 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 01/07/2025 |
13 | Acquisition by Smither John W of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 01/08/2025 |
14 | Acquisition by Van Der Kamp Hilde Johanna of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 01/21/2025 |
15 | Disposition of 23815 shares by Douglas Kling of NewAmsterdam Pharma at 23.46 subject to Rule 16b-3 | 01/27/2025 |
16 | Disposition of 5148 shares by Douglas Kling of NewAmsterdam Pharma at 21.93 subject to Rule 16b-3 | 01/28/2025 |
17 | NewAmsterdam Pharma to Present at Guggenheims SMID Cap Biotech Conference | 01/29/2025 |
18 | Disposition of 13578 shares by Douglas Kling of NewAmsterdam Pharma subject to Rule 16b-3 | 01/31/2025 |
19 | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/07/2025 |
20 | Disposition of 90782 shares by Douglas Kling of NewAmsterdam Pharma at 19.54 subject to Rule 16b-3 | 02/18/2025 |
21 | Disposition of 9218 shares by Douglas Kling of NewAmsterdam Pharma at 19.23 subject to Rule 16b-3 | 02/19/2025 |
22 | NewAmsterdam Pharma Company N.V. Among the Oversold Biotech Stocks to Buy Now | 02/24/2025 |
23 | NewAmsterdam Pharma reports FY results | 02/26/2025 |
24 | NewAmsterdam Pharma Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags | 02/27/2025 |
25 | NewAmsterdam Pharma Company N.V. Yearly Results Heres What Analysts Are Forecasting For This Year | 02/28/2025 |
26 | Disposition of 150000 shares by Louise Kooij of NewAmsterdam Pharma at 20.37 subject to Rule 16b-3 | 03/04/2025 |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.